Our targets represent previously unexplored mechanisms of tumorigenesis.

Accelerating the development of first-in-class therapeutics against significant new drug targets to improve cancer treatment.

Our Science

We are targeting new pathways to fight cancer at its core tumorigenic mechanisms. We combine our deep scientific foundation in molecular cancer biology, tumorigenesis, and cancer stem cell biology, with expertise in preclinical and clinical drug development to advance novel therapeutics to treat advanced cancers.

Follow the Science

Our Targets

Our targets represent previously unexplored mechanisms of tumorigenesis.

KDM4 is an epigenetic regulator that controls gene expression, cell proliferation, stem cell maintenance, apoptosis, and metastasis.

Learn More

LEFTY1 is a member of the transforming growth factor beta (TGF-β) superfamily that promotes long-term growth and self-renewal of cancer stem cells.

Learn More

Innovators in Our Field

Tachyon operates with a dedicated internal core development team and a broad virtual external network of expertise to achieve one goal – advance our programs with speed and innovation, without compromising the quality or integrity of our science.

Meet the tachyon team

Accelerating Science for Breakthrough Therapies